GW273225 clinical trials
Also written GW273225.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses GW273225 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GW273225
- 3
Studies by the year they started
3 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GW273225 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Oral Contraceptive Interaction Study for GW273225TerminatedPhase 1GlaxoSmithKlineNCT00483535Written as GW273225
- Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female VolunteersCompletedPhase 1GlaxoSmithKlineNCT00501865Written as GW273225
- GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial SeizuresWithdrawnPhase 2GlaxoSmithKlineNCT00567424Written as GW273225